

SYMPOSIA SERIES

Kidney Disease in the Genomic Era









Register at <https://www.natera.com/events/oh-symposias/>

Date & Time March 11, 2022 | 12:00 – 5:00 PM ET

Venue Boston Marriott Long Wharf | 296 State Street, Boston, MA 02109

Registration and parking are complimentary. Pre-registration is required.

Chair Martin Pollak, MD

11:40 – 1:00	Registration Open Onsite	
	Lunch & Learn	
12:00 – 12:45	Renaisight: Expanding the scope of genetic testing in Nephrology	 Trudy McKanna, MS CGC <i>Director, Medical Education, Natera</i>
1:00 – 1:10	Opening remarks	 Martin Pollak, MD <i>Professor of Medicine, Harvard Medical School Chief, Division of Nephrology Beth Israel Deaconess Medical Center</i>
1:10 – 1:40	A genetics primer: the basics and navigating a genetics report	 Renée Pelletier, MS, CGC <i>Program Manager & Genetic Counselor Genomic Medicine Unit Massachusetts General Hospital</i>
1:40 – 2:10	Practical application of genetic testing in nephrology	 Andrew Lundquist, MD, PhD <i>Assistant Clinical Director, Nephrology, Department of Medicine Massachusetts General Hospital</i>
2:10 – 2:40	Polycystic kidney disease: new horizons and therapeutic frontiers	 Peter G. Czarnecki, MD <i>Instructor of Medicine, Harvard Medical School Associate Physician, Division of Renal Medicine Director, Polycystic Kidney Disease Clinic Director, ICU Nephrology Service, Brigham and Women's Hospital</i>
2:40 – 3:10	The emerging role of genetic testing in transplant medicine	 Anil K. Chandraker, MD, MBChB <i>Medical Director, Kidney and Pancreas Transplantation Associate Professor, Harvard Medical School</i>
3:10 – 3:30	Break	
3:30 – 4:10	The future of genomic testing in nephrology	 Matt Sampson, MD, MSCE <i>Associate Professor of Pediatrics, Harvard Medical School Warren E. Grupe Chair in Nephrology, Boston Children's Hospital Associate Member, Broad Institute</i>
4:10 – 4:30	Impact of genetic testing: a patient perspective	 Alix Schwartz, MSW <i>Patient</i>
4:30 – 4:50	Panel question & answer	All
4:50 – 5:00	Closing remarks	Martin Pollak, MD
5:00 – 6:30	Reception with cocktails and hors d'oeuvres	

13011 McCallen Pass, Building A Suite 100 | Austin, TX 78753 | natera.com

The test described has been developed and its performance characteristics determined by the CLIA-certified laboratory performing the test. The test has not been cleared or approved by the US Food and Drug Administration (FDA). Although FDA is exercising enforcement discretion of premarket review and other regulations for laboratory-developed tests in the US, certification of the laboratory is required under CLIA to ensure the quality and validity of the tests. CAP accredited, ISO 13485 certified, and CLIA certified. © 2021 Natera, Inc. All Rights Reserved. OH_Symp_flyer1_20210104_NAT-8020826